MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Zentalis Pharmaceuticals Inc

Suletud

1.38 -12.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.35

Max

1.54

Põhinäitajad

By Trading Economics

Sissetulek

-7.3M

-47M

Müük

27M

27M

Aktsiakasum

-0.614

Kasumimarginaal

-176.706

Töötajad

166

EBITDA

5.3M

-46M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+294.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-11M

130M

Eelmine avamishind

14.04

Eelmine sulgemishind

1.38

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. sept 2024, 11:52 UTC

Suurimad hinnamuutused turgudel

Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies

18. juuni 2024, 11:59 UTC

Suurimad hinnamuutused turgudel

Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies

Võrdlus sarnastega

Hinnamuutus

Zentalis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

294.34% tõus

12 kuu keskmine prognoos

Keskmine 6.27 USD  294.34%

Kõrge 10 USD

Madal 2.2 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Zentalis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

5

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 1.76Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.